---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134767"
form_type: "8-K"
ticker: "SCLX"
cik: "0001820190"
company_name: "Scilex Holding Co"
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:15:19.917180+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Scilex forms JV to develop Phase 2 oral KDS2010 for obesity and Alzheimer's

## Summary
- Scilex contributes $50M of Semnur stock for controlling stake in Scilex Bio JV; IPMC holds 40%.
- NeuroBiogen grants Scilex Bio exclusive worldwide license to KDS2010 for all indications.
- KDS2010 is a reversible MAO-B inhibitor; Phase 1 shows favorable safety; Phase 2 ongoing in obesity and Alzheimer's.
- Obesity drug market forecast ~$150B by early 2030s; Alzheimer's market >$15B by 2030.

## SEC filing metadata
- accession: 0000950170-24-134767
- form_type: 8-K
- ticker: SCLX
- cik: 0001820190
- company_name: Scilex Holding Co
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1820190/000095017024134767/0000950170-24-134767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1820190/000095017024134767/sclx-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134767
- JSON: https://secwatch.observer/filing/0000950170-24-134767.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.